A randomized, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics and exploratory clinical activity of NM26-2198 in healthy subjects and in patients with moderate-to-severe atopic dermatitis (AD)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-503577-38-00

Acronym

NB-NM026-2198-101

Enrollment

Registered

2023-09-15

Start date

2023-12-07

Completion date

2024-10-01

Last updated

2024-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026